Xencor (XNCR) Other Non Operating Income (2013 - 2026)
Xencor (XNCR) posted quarterly Other Non Operating Income of $396000.0 for Q1 2026, up 1377.42% year-over-year from $26803.5 in Q1 2025, and up 5050.0% quarter-over-quarter from -$8000.0 in Q4 2025.
Powered by 
Analysis
Xencor (XNCR) Other Non Operating Income (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Other Non Operating Income for 14 consecutive years, with $396000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 1377.42% year-over-year to $396000.0; the TTM figure through Mar 2026 stood at $354000.0 (up 1763.16% YoY), while the FY2025 annual figure was -$73000.0, down 246.0% from the prior year.
- Other Non Operating Income grew to $396000.0 in Q1 2026 per XNCR's latest filing, from -$8000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.4 million in Q4 2023 and bottomed at -$1.4 million in Q1 2023.
- Historically, Other Non Operating Income has averaged $3500.0 across 5 years, with a median of -$9500.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 2350.0% — and 2023, when it surged 3347.62%.
- Xencor's Other Non Operating Income stood at -$42000.0 in 2022, then soared by 3347.62% to $1.4 million in 2023, then sank by 95.31% to $64000.0 in 2024, then sank by 112.5% to -$8000.0 in 2025, then surged by 5050.0% to $396000.0 in 2026.
- Business Quant data shows XNCR's Other Non Operating Income at $396000.0 in Q1 2026, -$8000.0 in Q4 2025, and -$17000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 434,000.00 |
| Mar 31, 2026 | 396,000.00 |
| Dec 31, 2025 | -8,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -17,000.00 |
| Mar 31, 2025 | -31,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -4,000.00 |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | -9,000.00 |
| Mar 31, 2023 | -1.39 Mn |
| Dec 31, 2022 | -42,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | -147,000.00 |
| Mar 31, 2022 | -96,000.00 |
| Dec 31, 2021 | -664,000.00 |
| Sep 30, 2021 | -593,000.00 |
| Jun 30, 2021 | -6,000.00 |